US3755581036 - Common Stock
Regulators are already on the case, and their findings will have financial impacts.
In the latest trading session, Gilead Sciences (GILD) closed at $79.02, marking a +1.24% move from the previous day.
Gilead Sciences experienced its first decline in six days, slipping 1.60% to $78.09.
Gilead Sciences experienced its first decline in six days, slipping 1.60% to $78.09.
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not meet the main goal in a mid-stage study. Merck's experimental drug, vibostolimab, in combination with its blockbuster drug Keytruda, failed to meaningfully slow disease progression and improve overall survival in patients with metastatic non-small-cell lung cancer. Gilead Sciences, Roche and GSK are among the drugmakers looking to grab a share of the lucrative cancer market focused on a protein believed to help cancer cells thwart immune system detection.
These three gene therapy stocks should get huge boosts over the long term from the use of gene editing techniques to treat diseases.
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
These stocks aren't popular on the market right now, but investors shouldn't let that scare them off.
The U.S. Food and Drug Administration said on Tuesday it was investigating the safety risk of CAR-T therapies made by companies such as Gilead and Johnson & Johnson after receiving reports of adverse events in patients. T-cell malignancies are a group of diseases caused by abnormal growth in T-cell, a type of white blood cell that helps the body in fighting infections. The FDA's investigation is also looking into currently approved cancer therapies in this class, including those from Bristol-Myers Squibb and Novartis AG.
The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.
The FDA on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies. Read more here.
There's no time like the present to buy these stocks.
Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.
"47 Ronin" director Carl Erik Rinsch reportedly used production funds from Netflix to place bets on Gilead Sciences stock, the S&P 500, and dogecoin.
Aurinia Pharmaceuticals (AUPH) experiences a 7.3% surge amidst takeover rumors, fueled by a reported visit from Gilead Sciences (GILD) corporate jet.
Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
The companies will work together on treatments for multiple myeloma and lymphomas.
The transaction includes cash the smaller biotech can use to develop its business.
Arcellx (ACLX) shares rise as Gilead (GILD) agrees to make a $200M equity investment in the immunotherapy developer as part of an expanded deal. Read more here.
Shares of Arcellx Inc. were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.’s Kite as...